Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress
This article was originally published in The Tan Sheet
Executive Summary
Efforts by firms and other pharmaceutical industry stakeholders to drive FDA's Safe Use Initiative agenda lower the likelihood of the agency intervening with enforcement action, according to Principal Deputy Commissioner Josh Sharfstein
You may also be interested in...
Dosing Directions, Measuring Devices Vary For OTC Meds, JAMA Study Says
Dosing directions and measuring devices for top-selling pediatric over-the-counter liquid medications were highly inconsistent as of November 2009, when the Food and Drug Administration issued voluntary industry guidelines in response to numerous reports of unintentional overdoses by children, according to a descriptive study of 200 such medications.
Dosing Directions, Measuring Devices Vary For OTC Meds, JAMA Study Says
Dosing directions and measuring devices for top-selling pediatric over-the-counter liquid medications were highly inconsistent as of November 2009, when the Food and Drug Administration issued voluntary industry guidelines in response to numerous reports of unintentional overdoses by children, according to a descriptive study of 200 such medications.
Dosing Directions, Measuring Devices Vary For OTC Meds, JAMA Study Says
Dosing directions and measuring devices for top-selling pediatric over-the-counter liquid medications were highly inconsistent as of November 2009, when the Food and Drug Administration issued voluntary industry guidelines in response to numerous reports of unintentional overdoses by children, according to a descriptive study of 200 such medications.